Ariad +4.3% AH, Daily Mail reports that pharmas are circling


Ariad Pharmaceuticals (ARIA) shares spike 4.3% AH, after the Daily Mail floats a rumor that industry majors including Eli Lilly, GlaxoSmithKline, and Shire "have been sniffing around" ever since Iclusig was given the green light by the FDA.

The paper throws out the number $20/share as the price the potential suitors may be willing to pay.

From other sites
Comments (18)
  • TruffelPig
    , contributor
    Comments (4207) | Send Message
     
    :) - good news. I am long this name since $3. $20 would be very very nice. But I think that is a tad stretched for a valuation.
    22 Jan 2014, 07:22 PM Reply Like
  • PaceSystem
    , contributor
    Comment (1) | Send Message
     
    $19 price coming soon
    22 Jan 2014, 07:55 PM Reply Like
  • ckrvarma
    , contributor
    Comment (1) | Send Message
     
    Really?? You think so??
    23 Jan 2014, 11:29 AM Reply Like
  • meched
    , contributor
    Comments (2) | Send Message
     
    What paper who wrote it? Where did this news come from?
    22 Jan 2014, 08:01 PM Reply Like
  • LongT
    , contributor
    Comments (10) | Send Message
     
    Came from a UK tabloid. Not too sure about reputation of this publication, but tabloids do actually break news from time to time.
    22 Jan 2014, 09:35 PM Reply Like
  • robauk
    , contributor
    Comments (3) | Send Message
     
    oh ya i really hope this happens a bigger pharma company, could take this drug to where it needs to be, because they have far more money to do it!, come on harvey
    22 Jan 2014, 08:03 PM Reply Like
  • ka Ip
    , contributor
    Comments (8) | Send Message
     
    that's a trap
    22 Jan 2014, 08:29 PM Reply Like
  • ka Ip
    , contributor
    Comments (8) | Send Message
     
    Real case AH volume should be over 0.1 billion shares !!!
    22 Jan 2014, 08:35 PM Reply Like
  • nick159
    , contributor
    Comments (83) | Send Message
     
    Well, I guess we'll see tomorrow where this rumor is going. Would any of these 3 Pharma's be willing to buyout Ariad for up to 3.8 billion? Hey, you never know.
    22 Jan 2014, 09:32 PM Reply Like
  • JrMastermind
    , contributor
    Comments (37) | Send Message
     
    If true, this suggests they have looked at the data and are convinced that Iclusig will be safe enough at lower doses to gain approval as a first line treatment.

     

    Big IF ...
    22 Jan 2014, 10:10 PM Reply Like
  • User 1716871
    , contributor
    Comment (1) | Send Message
     
    http://dailym.ai/1kZQYjr
    22 Jan 2014, 10:21 PM Reply Like
  • User 4247161
    , contributor
    Comments (343) | Send Message
     
    Thanks for link!
    22 Jan 2014, 10:30 PM Reply Like
  • Hoa Duong
    , contributor
    Comments (7) | Send Message
     
    Ariad was trading at $20+ all of four months ago.

     

    Consequently, 20 bucks a share for an outright buy might sound high but probably not too far from reality.
    23 Jan 2014, 05:19 AM Reply Like
  • HISTORY repeats itself
    , contributor
    Comments (107) | Send Message
     
    Iclusig is definitely the most promising TKI at this time in the market. It is the only treatment for T315 I mutated Chronic Myelogenic Leukemia patient . ARIA is presently running trial in Stage IV lung cancer . TKI's have Billions for large Pharma so it would not be at all surprising if Big Pharma are interested in ARIA. It was trading over $22 prior to the recent event regarding side effect of Iclusig but see how quicklt itcame back to market. I wouldnt be surprissed if Big Pharma statred sniffing around ARIA. I can tell you for sure Analyst are wrong about ARIA including Analyst saying it should be valued around $3 unfortunately when it crosses $10 these Analyst are not punished even though their clients lose a lot of money. If analyst were punished economically they would think twice may be a thousand times before making their fraudulant speculation regarding stock price. Even if ARIA is not acquired it would be north of $20 in 2 to 3 yrs, however on the way chances of it being aquired is high. Shorts are toast in this case thanks to the Analyst !!!
    23 Jan 2014, 08:16 AM Reply Like
  • MsTax
    , contributor
    Comments (4) | Send Message
     
    This stock is heavily manipulated. I am wondering how much power the news have over these manipulations, especially over the shorts. What is the estimated "high" for today? 12%? 20%? Back to 18$???

     

    I am bringing my popcorn to enjoy the show!
    23 Jan 2014, 08:49 AM Reply Like
  • ka Ip
    , contributor
    Comments (8) | Send Message
     
    It's trap
    23 Jan 2014, 10:22 AM Reply Like
  • djcodeman
    , contributor
    Comments (3) | Send Message
     
    Chartwise this would be very nice... and FILL THE GAP!
    23 Jan 2014, 08:54 AM Reply Like
  • Benyas
    , contributor
    Comments (84) | Send Message
     
    Yes, small biotech companies are manipulated by the stock market; even in this forum. Here are a few crumbs of actual information: 1. The speed of the reinstatement of Iclusig is almost unprecedented. 2. The TKI "113", now being tested against NSCLC (lung cancer) crosses the blood brain barrier. That means it can potentially treat brain metastases as well as lesions elsewhere. 3. 50,000,000 shares have already traded today and the price is rising. That means many people think there is truth in the current rumor of a buyout. The family that owns Fidelity Funds holds a huge position in Ariad. Yes, I have my own bias. Go Broncos! Go Ariad!
    23 Jan 2014, 03:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs